Loading...
Preserving ovarian function and fertility is a priority in young women who are treated for breast cancer. Animal studies and small uncontrolled trials in women have suggested that ovarian suppression during chemotherapy protects ovarian function. Accordingly, investigators in Egypt randomized 80 women (age range, 18–40) who had undergone surgery for early breast cancer to chemotherapy with or without a gonadotropin-releasing hormone (GnRH) agonist (goserelin [Zoladex], 3.6 mg subcutaneously at 28-day intervals for 6 months). All patients were treated with 5-fluorouracil, doxorubicin, and cyclophosphamide at 6- to 8-week intervals for 6 cycles; none received radiotherapy.
Among goserelin recipients, 90% resumed menses, and 69% resumed spontan…